Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Jin Hyoung Kang
- Target Recruit Count
- 28
- Registration Number
- NCT05477615
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hosptial, Seoul, Korea, Republic of
A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 64
- Registration Number
- NCT05469178
- Locations
- 🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland, United States
Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases
- Conditions
- Interventions
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Shanghai Pudong Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05459441
- Locations
- 🇨🇳
Fudan University Pudong Medical Center, Shanghai, Shanghai, China
A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Lantern Pharma Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05456256
- Locations
- 🇺🇸
Los Angeles Cancer Network, Fountain Valley, California, United States
🇯🇵Hokkaido Cancer Center, Sapporo-Shi, Hokkaido, Japan
🇯🇵Kanagawa Cancer Center Hospital, Yokohama-Shi, Kanagawa, Japan
A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- D3 Bio (Wuxi) Co., Ltd
- Target Recruit Count
- 392
- Registration Number
- NCT05410145
- Locations
- 🇪🇸
D3 Bio Investigative Site, Valencia, Spain
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 186
- Registration Number
- NCT05403385
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
🇺🇸Mid-Florida Hematology & Oncology Centers, PA, Orange City, Florida, United States
A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05386888
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT05364645
- Locations
- 🇺🇸
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
ATATcH Alternating Treatment Plans for Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 150
- Registration Number
- NCT05358548
- Locations
- 🇺🇸
RWJBarnabas Health - Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸RWJBarnabas Health - Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05335941
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.